Reports
Global Sickle Cell Disease Treatment Market: By Treatment: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Value Chain Analysis; Competitive Landscape; Industry Events and Developments
Global Sickle Cell Disease Treatment Market Outlook
The global sickle cell disease treatment market stood at a value of around USD 3.4 billion in 2020. The market is further expected to grow at a CAGR of 16.9% in the forecast period of 2023-2028 to attain a value of around USD 8.50 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increased Demand for Blood Transfusion Treatment to Bolster the Growth of the Global Sickle Cell Disease Treatment Industry
Based on treatment, the blood transfusion segment is predicted to account for a significant market share in the sickle cell disease treatment industry. This increase can be associated with the increased accessibility of blood transfusion treatment compared to other forms of treatment. In addition, blood transfusion helps to treat anaemia and prevent stroke. Furthermore, it is used to dilute the sickled haemoglobin with normal haemoglobin in order to treat chronic pain, acute chest syndrome, splenic sequestration, and other complications. Thus, this segment is estimated to positively catalyse the market growth in the forecast period.
North America to Occupy a Substantial Market Share in the Global Sickle Cell Disease Treatment Industry
North America is expected to occupy a substantial share of the sickle cell disease treatment industry in the forecast period. This growth can be attributed to the presence of a large African-American population in the region, which is more susceptible to sickle cell disease. In addition, the rising accessibility to resources and treatment facilities with increased disposable income and highly advanced healthcare infrastructure are also contributing to the growth. Meanwhile, in the African region, in countries such as Cameroon, the Republic of Congo, Gabon, Ghana, and Nigeria, the prevalence of sickle cell disease is between 20% and 30%. At the same time, it is as high as 45% in some parts of Uganda, as stated by the WHO. Moreover, in this region, the majority of children with the most severe form of the disease die prior to the age of 5, usually from an infection or severe blood loss. Thus, the growing awareness about sickle cell disease treatment and the improving healthcare facilities in Africa are expected to provide lucrative growth opportunities to the market.
Sickle Cell Disease Treatment: Market Segmentation
Sickle cell disease refers to a commonly found blood disorder. This disease is inherited by the children whose parents carry either sickle cell disease or sickle cell trait. This disease leads to abnormal haemoglobin generation, which is rigid and shaped like a sickle that can get stuck and block blood flow, which causes interference with oxygen delivery. This leads to pain, infections, stroke, acute chest syndrome, organ damage, and other disabilities. In addition, the drastic complications pertaining to sickle cell disease include premature death in some cases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By treatment, the market is divided into:
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Incidences of Sickle Cell Disease to Augment the Growth of the Global Sickle Cell Disease Treatment Industry
According to the WHO statistics, an estimated 5% of the world’s population carries trait genes for haemoglobin disorders, mainly sickle-cell disease and thalassaemia. In addition, more than 300,000 babies with severe haemoglobin disorders are born each year. The countries worldwide and international organisations are strategising initiatives to control and prevent sickle cell disease risks. Moreover, with the growing geriatric population worldwide, which is more susceptible to chronic disorders, governments are increasingly investing in the healthcare sector to reduce mortality risks. As a result, sickle cell disease treatment is in huge demand for the early detection of the disease. For instance, The Kidney Cancer Association (KCA) and the Sickle Cell Disease Association of America, Inc. (SCDAA) partnered to launch a programme called KNOW & TELL to raise awareness about sickle cell trait and its potential connection with a rare type of kidney cancer known as renal medullary carcinoma (RMC). Such initiatives are expected to augment the market growth in the forecast period.
Key Industry Players in the Global Sickle Cell Disease Treatment Market
The report gives a detailed analysis of the following key players in the global sickle cell disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Emmaus Life Sciences, Inc.
- Global Blood Therapeutics, Inc.
- bluebird bio, Inc.
- Pfizer Inc.
- Novartis International AG
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Treatment, Region |
| Breakup by Treatment | Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer Inc., Novartis International AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Sickle Cell Disease Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Sickle Cell Disease Treatment Historical Market (2018-2022)
8.3 Global Sickle Cell Disease Treatment Market Forecast (2023-2028)
8.4 Global Sickle Cell Disease Treatment Market by Treatment
8.4.1 Blood Transfusion
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Pharmacotherapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Bone Marrow Transplant
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.5 Global Sickle Cell Disease Treatment Market by Region
8.5.1 Market Share
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Emmaus Life Sciences, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Global Blood Therapeutics, Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 bluebird bio, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Pfizer Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Novartis International AG
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Sickle Cell Disease Treatment Market: Key Industry Highlights, 2018 and 2028
2. Global Sickle Cell Disease Treatment Historical Market: Breakup by Treatment (USD Billion), 2018-2022
3. Global Sickle Cell Disease Treatment Market Forecast: Breakup by Treatment (USD Billion), 2023-2028
4. Global Sickle Cell Disease Treatment Historical Market: Breakup by Region (USD Billion), 2018-2022
5. cc Forecast: Breakup by Region (USD Billion), 2023-2028
6. North America Sickle Cell Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
7. North America Sickle Cell Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
8. Europe Sickle Cell Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
9. Europe Sickle Cell Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
10. Asia Pacific Sickle Cell Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
11. Asia Pacific Sickle Cell Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
12. Latin America Sickle Cell Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
13. Latin America Sickle Cell Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Middle East and Africa Sickle Cell Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Middle East and Africa Sickle Cell Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Global Sickle Cell Disease Treatment Market Structure
Key Questions Answered in the Report
In 2020, the global sickle cell disease treatment market attained a value of nearly USD 3.4 billion.
The market is projected to grow at a CAGR of 16.9% between 2023 and 2028.
The major drivers of the industry include rising accessibility to resources and treatment facilities, increased disposable income, highly advanced healthcare infrastructure, growing awareness about sickle cell disease treatment, and increasing demand for blood transfusion treatment.
The key market trends guiding the growth of the industry include the increasing investments in the healthcare sector and growing geriatric population worldwide.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant segments based on treatment include blood transfusion, pharmacotherapy, and bone marrow transplant.
The major players in the industry are Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer Inc., and Novartis International AG, among others.
Analyst Review
The global sickle cell disease treatment market attained a value of USD 3.4 billion in 2020, driven by the growing initiatives to create awareness about the sickle cell disease by international organisations and governments. Aided by the rapid clinical advancements in the treatment technology and rising accessibility to resources and treatment facilities, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 16.9%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By treatment, the market can be distributed into blood transfusion, pharmacotherapy, and bone marrow transplant. The major regional markets for sickle cell disease treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer Inc., and Novartis International AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER